Innealta Capital’s PTC Therapeutics PTCT Stock Holding History

Innealta Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-36	Closed	-$1.1K	–	1295
2024 Q2	$1.1K	Buy	+36	New	+$1.17K	﹤0.01%	1289

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Innealta Capital's PTCT Position: Q3 2024 in Review

Innealta Capital sold out of PTC Therapeutics (PTCT) in Q3 2024, closing a stake of 36 shares — an estimated $1.1K sold.

Innealta Capital first reported a position in PTCT in Q2 2024 and held it in 1 quarter. The position peaked at $1.1K in Q2 2024. 203 funds tracked by Wall St. Rank hold PTCT as of Q3 2024.

Innealta Capital reported no remaining PTC Therapeutics position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 36 PTC Therapeutics shares in Q3 2024, an estimated $1.1K.
Innealta Capital first reported a position in PTC Therapeutics in Q2 2024 and held it in 1 quarter.
Innealta Capital's PTC Therapeutics position peaked at $1.1K in Q2 2024.
203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.